About Origin WW
Origin WW is a Healthcare company based in Princeton (United States) founded in 2010. Drug delivery platform for skin and soft-tissue infections is developed. Origin WW has raised $1.88 million across 3 funding rounds. Origin WW offers products and services including IonoJetâ„¢. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Diversified. Its legal entity is Origin Life Sciences, Inc. Its competitors include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Origin was founded in 2010 and is headquartered in Princeton, United States. The company operates in the biotechnology sector, focusing on a patented drug delivery platform called IonoJet. This technology facilitates targeted nitric oxide delivery from room air at the treatment site. Products developed include IonoStim for wound healing, Ionoderma for onychomycosis, Ionosite for arthritis and tendinitis, and Ionodent for periodontitis and implantitis, addressing various skin and soft-tissue conditions.
- Headquarters Princeton, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website originww.com
- Legal Name Origin Life Sciences, Inc.
- Total Equity Funding$1.88M (USD)
in 3 rounds
- Latest Funding Round$51K (USD), Seed
Oct 2023
Products & Services of Origin WW
Origin WW offers a comprehensive portfolio of products and services, including IonoJet™.
Generates nitric oxide for wound healing and infection treatment applications.
Funding Insights of Origin WW
Origin WW has successfully raised a total of $1.88M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $51 thousand completed in October 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.88M
- Total Rounds 3
- Last Round Seed — $51,000
- First Round $1.33M
(May 2017)
All 3 funding rounds of Origin WW with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $51,000 | Seed | – | – | – |
| Jun 2023 | $500,000 | Seed | – | – | – |
| May 2017 | $1.33M | Seed | – | – | – |
People of Origin WW
10 people are tracked at Origin WW (9 in leadership, 1 in board & advisors).
| Name | Role | Group |
|---|---|---|
Leigh Gourmand | VP, Finance & Controller | Leadership |
Kathleen Bannon | VP, Marketing, US Commercial Strategy | Leadership |
David Dantzker | Deputy Chairman and Chief Medical Officer | Leadership |
Michael Preston | Chairman & CEO | Leadership |
Johnny Fernandes | Chief Financial Officer | Leadership |
Ferid Murad | Chief Scientific Advisor | Leadership |
Anthony Brampton | Director | Leadership |
Terry Treadwell | Chief Clinical Officer Designate | Leadership |
Victor Micati | Director | Leadership |
Jerome Boda Korten | Director | Board & advisors |
Complete people profiles for Origin WW
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Origin WW
3 dated milestones of Origin WW across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Origin WW is founded.
- Funding First funding round of $1.3M.
- Funding Latest funding round, Seed, of $51K.
Competitors of Origin WW
Origin WW has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Vividion Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform |
Detailed competitors of Origin WW
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Origin WW
The website of Origin WW (originww.com) receives about 1.1K visits a month.
- Monthly visits1.1K
▼ 44.3% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Origin WW (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Origin Ww
Complete news archive for Origin WW
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Origin WW
Origin WW was founded in 2010 and raised its 1st funding round 7 years after it was founded.
Origin WW is headquartered in Princeton, United States. It is registered at Princeton, New Jersey, United States.
Origin WW is a funded company, having raised a total of $1.88M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.33M, raised on May 2017.
Origin was founded in 2010 and is headquartered in Princeton, United States. The company operates in the biotechnology sector, focusing on a patented drug delivery platform called IonoJet. This technology facilitates targeted nitric oxide delivery from room air at the treatment site. Products developed include IonoStim for wound healing, Ionoderma for onychomycosis, Ionosite for arthritis and tendinitis, and Ionodent for periodontitis and implantitis, addressing various skin and soft-tissue conditions.
Origin WW's top competitors include Sutro Biopharma, Avidity Biosciences and Vividion Therapeutics.
Origin WW offers IonoJetâ„¢.
Origin WW operates through Origin Life Sciences, Inc..